Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.

Study Overview

• Status: Completed
• Conditions: ADHD
• Intervention / Treatment: Drug: AMPH ER Tab 5, 10, 15 and 20 mg; Drug: AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg

Detailed Description

This is a randomized, double-blind (DB), placebo-controlled, parallel, study to assess the efficacy and safety of AMPH ER TAB compared to placebo for the treatment of ADHD in adults aged 18 to 60 years.

After Screening and Baseline evaluations are complete, eligible subjects will be randomized in the study to take DB AMPH ER TAB or matching placebo orally once daily in the morning beginning the day after the Baseline visit for 5 weeks. Dose will be titrated on a weekly basis to reach 20 mg per day. Subjects who cannot tolerate the study drug will be discontinued from the study.

A Math Test placement test will be done at Screening or at Baseline. At Visit 5, efficacy assessments will include the administration of serial Math Tests at pre-dose and at 0.5, 1, 2, 4, 8, 10, 12, 13, and 14 hours post-dose (Primary Endpoint) Adult Investigator Symptom Rating Scale (AISRS) and Clinical Global Impression Scale Severity (CGI-S) will be conducted at Baseline and Visits 1 to 5. Digit Symbol Substitution Test (DSST) will be administered at Baseline and Visit 5 (Secondary Endpoints).

Safety assessments will include treatment-emergent adverse events, physical examination, vital signs, body weight, Columbia Suicide Severity Rating Scale (C-SSRS), and direct questioning to assess for sleep, appetite, mood and psychotic events.

• Study Type: Interventional
• Enrollment (Actual): 130
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Florida
    • Bradenton, Florida, United States, 344201
      • Meridien Research
    • Maitland, Florida, United States, 32751
      • Meridien Research, Inc.
  • Nevada
    • Las Vegas, Nevada, United States, 89128
      • Center for Psychiatry and Behavioral Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria

1. Male or female aged 18 to 60 years, inclusive at the time of Screening.
2. Diagnosed with ADHD using the DSM-5 criteria based on the Adults ADHD Clinical Diagnostic Scale (ACDS).
3. IQ within normal range based upon clinical opinion of the Investigator.
4. Baseline AISRS total score greater than or equal to 26.
5. Baseline score of 4 or higher in CGI-S.

6. Females who participate in this study will be of childbearing or non-childbearing potential:

   • Childbearing potential: Physically capable of becoming pregnant

   • Non-childbearing potential:

     • Permanently sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation for at least 6 weeks or documented successful hysteroscopic sterilization); and/or
     • Post-menopausal (no menstrual period for at least 12 consecutive months without any other medical cause).
7. Females of childbearing potential must be non-lactating and must have a negative serum pregnancy test at Screening.
8. Willing to use acceptable, effective methods of contraception.
9. Be able to attend the clinic regularly and reliably.
10. Be able to understand, read, write, and speak English fluently to complete the study related materials.
11. Be informed of the nature of the study and give written consent prior to any study procedure.

Exclusion Criteria:

1. Current or lifetime history of bipolar disorder or any psychotic disorder as established by Mini International Neuropsychiatric Interview (M.I.N.I.) 7.0.2.
2. Current history of major depression, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, or post-traumatic stress disorder as established by the M.I.N.I. 7.0.2.
3. Known history of chronic medical illnesses including untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, and known family history of sudden death.
4. History of uncontrolled hypertension or a resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg. Subjects with well-controlled hypertension on a stable dose for at least 3 months of anti-hypertensives will be allowed to participate.

5. Have clinically significant findings in vital signs measurements at Screening including:

   • Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg
   • Heart rate >100 bpm

6. Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment:

   • Liver function test results ≥2 times the upper normal limit
   • Abnormal blood urea nitrogen, or creatinine levels
7. Clinically significant abnormal electrocardiogram or cardiac findings on physical examination (including the presence of a pathologic murmur).

8. Use of the following medications within 14 days of Baseline Visit:

   • Atomoxetine
   • Monoamine oxidase inhibitors (e.g., selegiline, isocarboxazid, phenelzine, tranylcypromine)
   • Tricyclic antidepressants (e.g., desipramine, protriptyline).

9. Use of the following medications within 3 days of Baseline Visit:

   • Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid hydrochloride [HCl], ascorbic acid)
   • Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts).
10. Use of fluoxetine within 30 days of Baseline Visit.
11. Use of stimulant medications within 1 week of Baseline Visit.
12. Planned use of prohibited drugs or agents from the Screening visit through the end of the study.
13. Participation in a clinical study in which an investigational drug was administered within 30 days prior to Screening.
14. Abnormal clinically significant laboratory test values at Screening that, in the opinion of the Medical Monitor or Sponsor, would preclude study participation.
15. Known history of allergy/hypersensitivity to amphetamine or any of the components of AMPH ER TAB.
16. Known history of lack of clinical response to amphetamine based upon Investigator judgment.
17. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
18. Any uncontrolled medical condition that, in the opinion of Medical Monitor or Sponsor, would preclude study participation.
19. History or presence of alcohol dependence or substance abuse disorder according to DSM-5 or within the last 12 months.
20. Subject's inability or unwillingness to follow directions from the study research staff.
21. Answer of "yes" to questions 4 or 5 of the C-SSRS within the last 2 years.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: AMPH ER Tab; Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg	Drug: AMPH ER Tab 5, 10, 15 and 20 mg; Amphetamine; Other Names: Amphetamine Extended Release Tablets
Placebo Comparator: Matching Placebo; Matching Placebo Tablets 5, 10, 15 and 20 mg	Drug: AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg; Placebo; Other Names: Amphetamine Extended Release Tablets Matching Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lean Squares Mean (± Standard Error) of Math Test Score Over All Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the Administration of Serial Math Tests at Visit 5 (Week 5)	The Total Math Score is the sum of the number of math problems attempted plus the number of math problems answered correctly and it provides an objective measure of performance that is time-sensitive, ADHD medication-sensitive, and well documented as a measure to evaluate ADHD medication effectiveness throughout the day. The Total Math Score ranges from 0-800 with higher scores indicating better performance.	Pre-dose to 14 hour post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in AISRS Total Score at Each Post-baseline Visit	AISRS scale was developed to better capture symptoms of ADHD in adult patients. The scale has 18 items scored as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). The maximum total score for the scale is 54 points.	Baseline, Visit 1 (week 1), Visit 2 (week 2), Visit 3 (week 3), Visit 4 (week 4), Visit 5 (week 5)
Change From Baseline to Visit 5 on DSST	The Digit Symbol Substitution Test (DSST) is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The DSST is sensitive to the presence of cognitive dysfunction as well as to change in cognitive function. The DSST is a 90 second test requiring participants to match symbols with numbers according to a code. Potential scores range from 0 to 100, and lower scores indicate worse performance.	From baseline to week 5
Change From Baseline on Total Math Test Score Over Each Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the Administration of Serial Math Tests at Visit 5 (Week 5)	The Total Math Score is the sum of the number of math problems attempted plus the number of math problems answered correctly and it provides an objective measure of performance that is time-sensitive, ADHD medication-sensitive, and well documented as a measure to evaluate ADHD medication effectiveness throughout the day. The Total Math Score ranges from 0-800 with higher scores indicating better performance.	Visit 5 (week 5)
Change From Baseline in CGI-S Total Score at Each Post-baseline Visit	The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.	Baseline, Visit 1 (week 1), Visit 2 (week 2), Visit 3 (week 3), Visit 4 (week 4), Visit 5 (week 5)

Collaborators and Investigators

• Sponsor: Tris Pharma, Inc.
• Collaborators: Premier Research Group plc
• Investigators: Principal Investigator: Andrew J. Cutler, MD, Meridien Research Inc.

Publications and helpful links

General Publications

• Cutler AJ, Childress AC, Pardo A, Duhoux S, Gomeni R, Rafla E, King TR, Kando JC. Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry. 2022 Jul 20;83(5):22m14438. doi: 10.4088/JCP.22m14438.

Study record dates

Study Major Dates

• Study Start (Actual): February 6, 2019
• Primary Completion (Actual): October 19, 2019
• Study Completion (Actual): October 19, 2019

Study Registration Dates

• First Submitted: February 4, 2019
• First Submitted That Met QC Criteria: February 6, 2019
• First Posted (Actual): February 8, 2019

Study Record Updates

• Last Update Posted (Actual): November 2, 2023
• Last Update Submitted That Met QC Criteria: October 11, 2023
• Last Verified: December 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Dopamine Agents; Dopamine Uptake Inhibitors; Central Nervous System Stimulants; Sympathomimetics; Adrenergic Uptake Inhibitors; Amphetamine
• Other Study ID Numbers: TRI108-ADD-400

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No